Hohmann, Christopher
Lutz, Magnus
Vignali, Sheila
Borchert, Kathrin
Seidel, Karolin
Braun, Sebastian
Baldus, Stephan
Näbauer, Michael
Funding for this research was provided by:
Universitätsklinikum Köln
Article History
Received: 28 March 2022
Accepted: 19 June 2022
First Online: 4 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: C. Hohmann receives lecture/consultancy fees from Actelion, Bayer, Daiichi Sankyo, MSD, and Pfizer. M. Lutz and S. Vignali are employees of Daiichi Sankyo Deutschland GmbH. K. Borchert, K. Seidel, and S. Braun are employed by Xcenda GmbH which received consulting fees for the execution of the study from Daiichi Sankyo Deutschland GmbH. S. Baldus receives direct personal payment (speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member) from Edwards Lifescience, Bayer Vital, CVRx, MSD Sharp & Dome GmbH, JenaValve Technology, Daiichi Sankyo, and Abbott and travel and meeting support from Bayer Vital, Novartis, Jena Valve Technology, Daiichi Sankyo, and Abbott. M. Näbauer received lecture fees from Bayer Healthcare, Daiichi Sankyo, Bristol-Myers-Squibb, and Pfizer.